Cost effectiveness of a novel swallowing and respiratory sensation assessment and a modelled intervention to reduce acute exacerbations of COPD

一项新型吞咽和呼吸感觉评估方法以及一项旨在减少慢性阻塞性肺疾病急性加重的模拟干预措施的成本效益分析

阅读:1

Abstract

Swallowing impairment observed in ~ 20% of people with Chronic Obstructive Pulmonary Disease (COPD) may increase the risk of aspiration pneumonia and acute exacerbations. We designed a decision analytic model to assess the cost-effectiveness of the Swallowing and Respiratory Sensation Assessment (SwaRSA) tests and swallowing rehabilitation to reduce COPD exacerbations. We believe that swallowing rehabilitation to improve coordination of swallowing and breathing may reduce exacerbations in people with COPD.From the Australia health system perspective, we assessed the cost effectiveness of four tests relative to standard of care, or no testing, over a time horizon of one year. The SwaRSA tests assessed relative to a standard of care arm of no testing: included the Eating Assessment Tool (EAT-10) score, Swallowing Capacity of Liquids, Tongue Strength Assessment, and Respiratory Sensation Assessment, in people with moderate to severe COPD. Outcome measures were COPD exacerbations per year, which were converted into quality adjusted life years (QALYs). Model inputs including costs, test sensitivities and specificities, COPD exacerbation risks, and exacerbation-related utilities were derived from published sources. Our assumptions on the costs, recovery, and risk reduction are based on the available data on pulmonary rehabilitation in COPD.Relative to no-SwaRSA, three individual testing strategies were found to be cost-effective at incremental cost effectiveness ratio per QALY ranging from $27,000 to $37,000 AUD assuming a willingness to pay of $50,000 AUD. The EAT-10 and the tongue strength were the two dominant options on the cost-effectiveness frontier. Model results were robust to variations in one-way and probabilistic sensitivity analyses.In COPD, SwaRSA modelling suggests that self-assessment with the EAT-10 and subsequent intervention is highly cost-effective relative to no-SwaRSA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。